GlassScriptPhysician profile
Jared B Hossack
NPI 1316106636
$9,471.49
in general payments reported to CMS, 2019-2025
35 companies · $2,422 in 2025
The $2,422 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,385 · 2020: $431 · 2021: $516 · 2022: $874 · 2023: $1,471 · 2024: $2,373 · 2025: $2,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,167 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,166.79 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,312.51 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,329.70 | 2019-2025 | Xifaxan, Plenvu, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $856.44 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $749.29 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Celgene Corporation | $430.24 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $311.31 | 2025 | Rezdiffra |
| Pfizer INC. | $283.92 | 2019-2025 | |
| Lilly USA, LLC | $272.44 | 2024-2025 | Omvoh |
| Genzyme Corporation | $249.66 | 2023-2025 | |
| Ardelyx, INC. | $220.96 | 2023-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $204.59 | 2019-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $182.82 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $154.13 | 2024-2025 | Voquezna |
| Medical Device Business Services, INC. | $120.00 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $102.21 | 2024-2025 | Iqirvo, Bylvay |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $75.47 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $68.99 | 2019-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $66.20 | 2024 | |
| Amgen INC. | $54.76 | 2025 | Uplizna |
| Braintree Laboratories, INC. | $48.96 | 2022-2023 | Sutab, Suflave |
| Novo Nordisk INC | $40.24 | 2025 | Wegovy |
| Biofire Diagnostics, LLC | $37.68 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $36.70 | 2024-2025 | Rapide Balloons, Lesionhunter |
| Vivus LLC | $35.17 | 2019-2020 | |
| Shire North American Group INC | $31.89 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.75 | 2023-2024 | Cyltezo |
| Amag Pharmaceuticals, INC. | $26.46 | 2019 | |
| Aimmune Therapeutics, INC. | $24.77 | 2025 | Zenpep |
| Ferring Pharmaceuticals INC. | $19.48 | 2023 | Rebyota |
| Sandoz INC. | $17.48 | 2023 | Hyrimoz |
| Qol Medical, LLC | $16.89 | 2019 | |
| Covidien LP | $16.06 | 2019 | |
| Evoke Pharma, INC. | $15.37 | 2023 | Gimoti |
| Redhill Biopharma INC. | $13.74 | 2020 | |
| Capsovision, INC. | $13.21 | 2024 | Capsocam Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Hossack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.